Ashington Innovation PLC Update on Cell Therapy and Calon Discussions (3475L)
September 05 2023 - 1:00AM
UK Regulatory
TIDMASHI
RNS Number : 3475L
Ashington Innovation PLC
05 September 2023
Press Release
5 September 2023
Ashington Innovation plc
("Ashington" or "the Company")
Update on Cell Therapy Ltd and Calon Cardio-Technology Ltd
Discussions
Change of Broker
Ashington Innovation plc (LSE: ASHI; FSE: 6FW), a special
purpose acquisition company, announces that further to the
announcement of August 24, the Company continues to pursue
negotiations to acquire Cell Therapy Limited ('Cell Therapy') and
Calon Cardio-Technology Limited ('Calon') in accordance with the
signed heads of terms.
By way of clarification, the proposed acquisition of Calon is
dependent on a successful close of the Cell Therapy transaction.
However, the proposed acquisition of Cell Therapy is not dependent
on an acquisition of Calon.
Ashington can confirm that discussions have continued between
the parties and that the Company is continuing its formal due
diligence process. As no binding agreement has yet been reached,
the Company cannot guarantee that either proposed acquisition will
complete.
Ashington also announces that following a breach of
confidentiality by its broker, SI Capital, the appointment of SI
Capital has been terminated and the Company is seeking to appoint a
new sole broker experienced in the transactions being considered
which is in line with its broader strategy to create a material
regenerative medicine group.
The Company will provide further updates as and when
appropriate.
For further information please contact:
Ashington Innovation plc
David Orchard via Tancredi +44 207 887
General Counsel 7633
-------------------------
Tancredi Intelligent Communication
Media Relations
-------------------------
Helen Humphrey
Charlie Hobbs + 44 7449 226 720
Jasmine Gadhavi +44 7897 557 112
ashington@tancredigroup.com +44 7931 435 236
-------------------------
About Ashington Innovation plc
Ashington Innovation PLC is a special purpose acquisition
company (SPAC), formed with the intention of acquiring businesses
operating in the technology sector.
The Company believes that in the increasingly fast-changing
global environment there will be an abundance of opportunities to
acquire existing businesses in the technology sector, and in
particular businesses that possess and utilise proprietary
technologies and own applicable intellectual property.
The Company is not limited to any specific geographic region in
identifying its target companies.
www.ashingtoninnovationplc.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDFFFSFAIISIIV
(END) Dow Jones Newswires
September 05, 2023 02:00 ET (06:00 GMT)
Ashington Innovation (LSE:ASHI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Ashington Innovation (LSE:ASHI)
Historical Stock Chart
From Nov 2023 to Nov 2024